Brevel, an Israeli microalgae-based ingredients startup, has inaugurated its first commercial plant in Israel to manufacture its new patented microalgae protein powder. The first products from this facility are slated for rollout in Q1 2025.

The new 27,000 sq feet (2,500 sq m) facility will house the company’s headquarters, an R&D center, and a large-scale commercial manufacturing area. It will also feature multiple bioreactors of varying capacities, including its first 5,000-liter bioreactor, enabling it to produce hundreds of tons of microalgae protein annually.

Brevel’s flagship microalgae protein is extracted from chlorella microalgae utilizing proprietary technology that combines fermentation and photosynthesis in indoor, fully automated reactors. According to the company, this ingredient is comparable in price and functionality to commonly used soy and pea proteins.

Analyst QuickTake: Brevel’s USD 18.5 million in a seed funding round facilitated the construction of this plant, which was intended for further development of its protein and expansion of operations. This facility is the first of two planned constructions, with the second facility slate for 2025, expected to have a total capacity of 900,000 l.